Abstract
The unique ability of dendritic cells to pick up antigens and to activate naive and memory CD4+ and CD8+ T cells raised the possibility of using them to trigger a specific anti-tumor immunity. If numerous studies have shown a major interest in dendritic cell-based vaccines for cancer immunotherapy in animal models, only a few have been carried out in human cancers. In this review, we describe recent findings in the biology of dendritic cells that are important to generate anti-tumor cytotoxic T cells in vitro and we also detail clinical studies reporting the obtention of specific immunity to human cancers in vivo using reinfusion of dendritic cells pulsed with tumor antigens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tarte, K., Klein, B. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 13, 653–663 (1999). https://doi.org/10.1038/sj.leu.2401394
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401394
Keywords
This article is cited by
-
Stem cell factor produced by tumor cells expands myeloid-derived suppressor cells in mice
Scientific Reports (2020)
-
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor
Cancer Immunology, Immunotherapy (2003)
-
The enhanced green fluorescent protein as a marker for human tumor cells labelled by retroviral transduction
Chinese Journal of Cancer Research (2002)
-
Gene delivery by attenuated Salmonella typhimurium : Comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination
Cancer Gene Therapy (2001)
-
Establishment of a follicular lymphoma cell line (FLK-1) dependent on follicular dendritic cell-like cell line HK
Leukemia (2001)